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ABSTRACT 
 
DEVELOPMENT OF A PROTOCOL TO MEASURE GENE EXPRESSION 
IN THE MOUSE TIBIA 
 
Daniel Hoover 
 
Numerous molecular factors active in bone tissue direct fracture repair and remodeling 
which can be altered by disease conditions such as Peripheral Arterial Disease (PAD) and 
Osteoporosis. Methods of molecular biology are commonly applied to investigate the 
expression and role of these molecular factors.  This project presents a robust three-step 
protocol for examining gene expression in the mouse tibia.  The protocol begins with 
isolating RNA from a flash frozen tibia sample. The isolated RNA is reverse transcribed 
into cDNA. Finally, PCR is performed to indentify expressed genes. Establishing this 
protocol will allow further research into the mechanisms of bone remodeling and repair. 
For example, this approach can be used to examine the relationship between osteocyte 
apoptosis and angiogenesis in bone tissue, with applications to ischemic conditions and 
osteoporosis. 
 
Keywords: osteocyte, angiogenesis, microcirculation, osteoporosis, fracture, molecular, 
gene expression, remodeling, electrophoresis, PCR, reverse transcription, isolation, RNA 
       iv 
ACKNOWLEDGEMENTS 
 
Dr. Trevor Cardinal – for introducing me to research, advising me during this project, and 
providing wise counsel regarding academics and career. 
 
Andrew Tilton – for providing much needed help with all things mol bio. 
 
Tyler Smith, Josh Cutts, Paul Heckler – for being “on-call” to extract tibiae. 
 
Hannah Forbes Project Fund – for funding this senior project. 
 
 
 
 
 
 
 
 
 
 
“It is my deepest belief that only by giving our lives do we find life.” 
-Cesar Estrada Chavez 
       v 
 
TABLE OF CONTENTS 
 
Section             Page 
 
I Introduction ________________________________________________________ 1 
Project Goal _______________________________________________________________ 1 
Background: Osteoporosis and PAD ___________________________________________ 1 
Osteoporosis ________________________________________________________ 1 
Peripheral Arterial Disease (PAD) _______________________________________ 7 
Link Between PAD and Osteoporosis ____________________________________ 7 
Background: Genes of interest:________________________________________________ 8 
Project Plan _______________________________________________________________ 10 
II Methods __________________________________________________________ 12 
Methods Overview _________________________________________________________ 12 
Methods Observed _________________________________________________________ 12 
III Results __________________________________________________________ 16 
IV Discussion _______________________________________________________ 19 
Success of Methodology _____________________________________________________ 19 
Potential Improvements _____________________________________________________ 19 
Future Research ___________________________________________________________ 20 
V References ________________________________________________________ 21 
VI Appendix A: Protocols ______________________________________________ 24 
Bone RNA Isolation Qiagen Mini Lipid Tissue Kit _______________________________ 24 
Reverse Transcription Agilent AffinityScript Kit ________________________________ 25 
Gel Electrophoresis and Spectrophotometry ____________________________________ 26 
Design and Order Primers __________________________________________________ 27 
VII Appendix B: Experimental Setup ____________________________________ 28 
RNA Isolation Equipment ___________________________________________________ 28 
RT and PCR Equipment ____________________________________________________ 28 
Comprehensive Reagents/Equipment List ______________________________________ 30 
 
       vi 
 
LIST OF FIGURES 
 
Figure              Page 
Figure 1 - Histology of Osseous Tissue 1............................................................................ 3 
Figure 2 - Cell Types and Their Roles in Bone Remodeling 5. .......................................... 4 
Figure 3 - Diagram of Remodeling in Cortical Bone 5. ...................................................... 5 
Figure 4 - Photomicrograph of Remodeling in Cortical Bone 5. ........................................ 5 
Figure 5 - Diagram of Remodeling in Trabecular Bone 5. .................................................. 5 
Figure 6 - Photomicrograph of Remodeling in Trabecular Bone 5. .................................... 6 
Figure 7 - Quality RNA.Results ....................................................................................... 16 
Figure 8 - PCR Results. .................................................................................................... 17 
Figure 9 - BioSpec Pulverizer (left) and Tissue Tearor (right). ........................................ 28 
Figure 10 - Nanodrop spectrophotometer for assaying RNA concentration and purity. .. 28 
Figure 11 - Gel electrophoresis apparatus. ....................................................................... 28 
Figure 12 - BioRad Gradient Thermocycler C1000 (left) and display (right). ................. 29 
 
       vii 
 
LIST OF TABLES 
 
Table              Page 
Table 1 - Signal factor molecules related to Osteoporosis, PAD, and fracture healing. .... 9 
Table 2 - Tibia Extraction Overview ................................................................................ 12 
Table 3 - RNA Isolation Overview ................................................................................... 13 
Table 4 - Reverse Transcription Overview ....................................................................... 13 
Table 5 - Thermocycler Protocol Design .......................................................................... 14 
Table 6 - PCR Overview ................................................................................................... 14 
Table 7 - Gel Electrophoresis Overview ........................................................................... 15 
Table 8 - Primers ............................................................................................................... 17 
Table 9 - Reagents/Equipment List................................................................................... 30 
 
       1 
I Introduction 
Project Goal 
The purpose of this project was to develop a method for studying gene expression 
in mouse tibiae. Specifically, a protocol for analyzing gene expression of the mouse tibia 
was needed to pioneer a new area of research into the molecular factors governing 
osteocyte behavior under disease conditions such as PAD or Osteoporosis. This protocol 
was built on a collection of established methods and required a quarter of 
experimentation designed to adjust the existing protocols to overcome specific difficulties 
associated with bone tissue. A reliable and accurate method of studying gene expression 
in the mouse tibia was created to ensure that molecular biology continues to complement 
ongoing research into angiogenesis and bone microcirculation. Bone-vasculature 
interactions are many and manifold, but the immediate areas of application of this project 
are to the pathologies of Peripheral Arterial Disease (PAD) and Osteoporosis.  
Background: Osteoporosis and PAD 
Osteoporosis 
Overview of Osteoporosis 
The World Health Organization quantifies the impact of a disease by the number of 
disability-adjusted life years (DALYs) it costs the population. In American and Europe, 
fractures resulting from osteoporosis create about 2.8 million DALYs each year 6. Half of 
postmenopausal women are predicted to have an osteoporosis related fracture and older 
men are also at risk. The fracture itself has less life impact than the pain, loss of 
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independence, impaired ambulation, depression, and nursing home admission that often 
follow 7. Biologically, osteoporosis has several characteristics. First, there is an overall 
decrease in bone density resulting in weaker bone. Second, osteocytes suffer a loss of 
viability. Osteocyte function is critical for bone health and their deterioration has a 
serious impact on bone remodeling and bone composition regulation 1. Third, in 
cancellous bone, osteoporosis results in fewer, narrower trabeculae that are no longer 
interconnected in the strong lattice framework of healthy bone 2. 
Normal Bone Structure 
Two types of bone tissue are present in the human body: cortical or compact bone, 
and cancellous or trabecular bone. The basic structural unit of compact bone is the 
osteon, consisting of concentric ring-like layers of matrix, termed lamellae, surrounding a 
central canal (see Figure 1 below) 1. Collagen fibers interweave through compact bone 
tissue and vasculature clusters run through canals in the matrix, supplying oxygen and 
nutrients. Osteocytes inhabiting tiny lacunae sense strain conditions on bone and regulate 
remodeling activities. Trabecular bone is less dense than compact bone and features 
spindly trabeculae, thin spines, and plates of bone lattice that develop along principal-
stress directions. Within the trabecular framework are cavities containing bone marrow. 
Trabecular bone is optimized for strength with a minimum weight of bone. It is found at 
the ends of long bones and in the middle of many other bone structures always enclosed 
by compact bone 1. 
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Figure 1 - Histology of Osseous Tissue 1. 
 
Normal Bone Remodeling 
Bone remodeling is both a normal response to changing stress conditions and a 
standard repair mechanism to compensate for daily wear. Remodeling is initiated by 
osteocytes responding to their environment 2. Osteocytes perceive stresses and strains that 
correspond to microcracks in the bone, and release signaling factors that trigger 
remodeling.  In damaged or growing regions, bone endothelium recruits osteoclasts using 
the RANKL/OPG system which will be discussed in more detail later 2, 3. Bone 
remodeling is performed by the Basic Multicellular Unit (BMU) which is made up of 
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osteoclasts, osteoblasts, and osteocytes 3. Osteoclasts function to resorb old or damaged 
bone (see Figure 2). They produce VEGF for the early stages of remodeling, which acts 
in a variety of capacities to encourage remodeling 3. Osteoblasts deposit new bone (see 
Figure 2). Remodeling occurs in cycles beginning with resorption by the osteoclasts and 
ending with osteoblast deposition of fresh bone. In normal cancellous bone, remodeling 
takes place on the surface of the trabeculae with an average cycle duration of 200 days 
(see Figures 5 and 6 below). Resorption occurs relatively quickly, in 30-40 days, while 
bone formation occurs over a period of 150 days 3. In cortical bone, osteoclasts travel in 
resorbing “cutting cones” and are directly followed by osteoblasts that refill the 
resorption cavity with new bone as shown in Figures 3 and 4 below. The remodeling 
cycle in cortical bone is shorter than the remodeling cycle in trabecular bone; in cortical 
bone, it has a median length of 120 days 3, 4. 
 
 
Figure 2 - Cell Types and Their Roles in Bone Remodeling 5. 
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Figure 3 – Diagram of Remodeling in Cortical Bone 5. 
 
 
Figure 4 – Photomicrograph of Remodeling in Cortical Bone 5. 
 
 
Figure 5 – Diagram of Remodeling in Trabecular Bone 5. 
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Figure 6 – Photomicrograph of Remodeling in Trabecular Bone 5. 
 
Osteoporotic Bone Remodeling and Treatments 
Bone remodeling continues under osteoporotic conditions, but it contributes to the 
diseased state rather than restoring bone structure. Osteoblast function is impaired, 
lagging far behind counterpart osteoclast activity. In normal bone remodeling, the 
remodeling cycle ends with a complete refilling of the resorption lacuna; in osteoporotic 
bone, the osteoblasts are unable to refill the entire cavity. Bone density is lost with each 
cycle of remodeling 3. There are several treatments currently available for osteoporosis 
that target various biochemical pathways in bone. Treatment with Bisphosphonates 
targets the inhibition of osteoclast activity. Preventing osteoclast resorption effects a 
healthy increase in bone density. Unfortunately, complex instructions for administering 
this treatment result in inconsistent adherence to long term therapy 8. In addition, there is 
concern that bisphosphonates over-inhibit bone remodeling, impairing fracture repair and 
allowing bone microcracks to accumulate 9. Treatment with Strontium Ranelate increases 
bone formation and decreases bone resorption 10. Its mechanism of action is not well 
understood and may have unforeseen drawbacks as is the case with other modern 
treatment strategies. There are no treatments for osteoporosis that focus on the impaired 
vascular system even though the vasculature heavily influences bone remodeling 2. 
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Peripheral Arterial Disease (PAD) 
Peripheral arterial disease (PAD) is a serious chronic condition of the vasculature. 
Blood vessels are occluded by atherosclerotic plaques, impairing blood circulation. The 
disease’s effects are most noticeable in the extremities; in the early stages, PAD causes 
claudication: intermittent pain during ambulation. In the late stages, PAD progresses to 
ischemic ulceration and gangrene ultimately resulting in amputation in 30 percent of 
cases 11. Plaques are formed over time by the accumulation of ox-LDL, oxidized low 
density lipoprotein, in the subendothelial space 2. The body responds with acute dilation 
of collateral vessels to redirect some of the blocked flow. When PAD persists, the chronic 
response of the vasculature is to remodel itself to provide less collateral resistance. The 
end result however is an exhaustion of the vasculature’s ability to compensate and a 
severe reduction in the body’s vasodilation and vessel repair capacity 2. 
Link Between PAD and Osteoporosis 
The conception of a link between these two pathologies is fascinating and 
compelling for several reasons. The diseases share common risk factors such as older 
age, physical inactivity, smoking, and diabetes mellitus 12. The intermittent claudication 
of PAD restricts physical activity and results in less mechanical stimulation of the bone 
and less impetus for remodeling 2. PAD often occurs concurrent with low bone mineral 
density (BMD). Decreases in bone formation and overall bone mass have been previously 
linked to deficiencies in the vasculature network and PAD-affected vasculature is 
deficient in many ways 19. 
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The potential for PAD and osteoporosis interaction exists because they share the 
same biological pathways and similar marker molecules 12. In order for bone regeneration 
to take place, angiogenesis must occur to some degree. PAD affected vasculature is 
impaired in its ability to undergo both angiogenesis and arteriogenesis. Thus, PAD’s 
adverse affects on bone remodeling may contribute to osteoporosis. There may exist a 
specific connection centering on the relationship between osteoprotegerin (OPG), RANK, 
and RANKL 2. These three molecules work together to regulate remodeling. The excess 
osteoclast activity of osteoporosis stimulates OPG production to suppress that osteoclast 
activity. The increase in OPG also disrupts the RANK / RANKL interaction that 
ordinarily stimulates angiogenesis, leading to a potential lack of the angiogenesis that 
ordinarily should accompany bone remodeling 2. Finally, both disease states are vitamin 
D deficient and vitamin D therapy has been very successful in patients with PAD and 
osteoporosis 2, 12. The reason for these successes could be the general physical inactivity 
of patients suffering from each disease. Physical inactivity is common associated with a 
lack of vitamin D absorption from the sun. In conclusion, although there is more 
correlation than causal evidence at present, this hypothesized relationship between PAD 
and osteoporosis is well worth exploring. 
Background: Genes of interest: 
For this study, six osteocyte genes of interest were selected to design primers (see 
Table 1 below). These are expressed in bone tissue at varying times during the 
progression of PAD, the disease of osteoporosis, and fracture healing. Studying the 
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expression of these and similar factors under different experimental conditions will 
advance the current knowledge of molecular mechanisms in bone. 
Table 1 - Signal factor molecules related to Osteoporosis, PAD, and fracture healing. 
Signal Factor / Molecule Functions 
Cytokines (TNF-α) 
IL-1, IL-6, TNF-α 
Cytokines contribute to osteoclast activation and 
bone resorption 2. TNF-α stimulates OPG production 
to suppress osteoclast activity 2. They are expressed 
at high levels during days 1 through 3 of bone 
remodeling. Cytokines increase extracellular matrix 
synthesis and attracts other inflammatory cells.  They 
promote angiogenesis as well as bone resorption 15. 
 
TGF-β (TGFβ-1) 
Transforming Growth 
Factor Beta Superfamily 
 
The factors of the TGF-β superfamily are key 
regulators of bone development and repair 14. They 
target mesenchymal stem cells and osteoprogenitors 
and incite cell proliferation of bone forming cells. 
TGF-β increases the density of the extracellular 
matrix (ECM) and is released throughout fracture 
healing process 15. 
 
BMPs (BMP2) 
Bone Morphogenetic Proteins 
 
BMPs promote differentiation of mesenchymal cells 
into chondrocytes and osteoblasts, and 
osteoprogenitors into osteoblasts 15. In addition, they 
may stimulate VEGF synthesis 15. Their expression 
during fracture healing takes many patterns. 
 
VEGFs (VEGFa) 
Vascular Endothelial 
Growth Factors 
The degree of collateral arteriogenesis depends on 
the extent of  VEGF and VEGF-A gene expression 2. 
For angiogenesis, VEGF incites proliferation and 
differentiation of endothelial cells (ECs). The higher 
the concentration of VEGF, the more EC 
proliferation and differentiation. VEGF also 
stimulates EC proliferation during endochondral 
formation in the case of fracture 15. It can increase the 
rate of fracture repair when administered 
exogenously 20. 
 
Angiopoietins (Ang1 & Ang2) 
 
The angiopoietins affect the development of larger 
vessels and structures such as collateral branches 15. 
The angiopoietin pathway co-regulates angiogenesis 
with VEGF. 
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Project Plan 
As alluded to previously, the behavior of a tissue can be characterized to some 
extent by studying the gene expression of its cells. In this case, the protocol was created 
to analyze those signaling factors and molecules active in bone tissue by studying the 
gene expression of the bone cells. These bone cells contain genetic code in the form of 
DNA that is capable of encoding the factors of interest upon activation. The actual 
expression of a gene depends on the input the cell is receiving at that point in time. If the 
cell is triggered to produce a given factor by external stimuli, then it will transcribe 
messenger RNA from the DNA that codes that factor. The messenger RNA will be 
translated by ribosomes that assemble the protein or enzyme of interest. The point at 
which molecular biologists often intervene is after the DNA has transcribed mRNA. The 
protocol presented here begins with the isolation of mRNA from the bone cells. 
To obtain gene expression data from the mRNA, three steps were performed post-
isolation. First, the fragile mRNA was reverse transcribed into double stranded dsRNA or 
cDNA. cDNA is less vulnerable to destruction by environmental RNases and can also be 
used as starting material for PCR, Polymerase Chain Reaction. Second, a PCR reaction 
was run on the newly created cDNA. PCR functions to amplify a low concentration of 
cDNA fragments into quantities large enough to visualize 21. Primers bind specific 
genetic material from the assortment of cDNA fragments. For this study, primers were 
selected to bind cDNAs corresponding to the genes of interest in Table 1. These cDNAs 
were amplified during PCR and then visualized by electrophoresis and imaging under UV 
light. PCR amplicons were identified by base pair length, corresponding to distance 
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traveled during electrophoresis. If an amplicon was present for a given gene, then that 
gene was being expressed, encoding mRNA to produce a certain protein or enzyme by 
translation. 
RNA is difficult to extract from highly mineralized bone matrix but special 
reagents such as QIAzol make extraction possible. The contingency plan, if the Qiagen 
reagents failed, was to use a Trizol two step method of RNA isolation. 
In conclusion, the project plan was to develop a protocol for analyzing the gene 
expression in mouse tibia; its essential components were RNA isolation, the reverse 
transcription of cDNA, primer design and PCR, and gel electrophoresis. This protocol 
will augment research into osteocyte activity in Osteoporosis and PAD. 
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II Methods 
Methods Overview 
Each tibiae was surgically extracted from the mouse and frozen for storage to 
prevent degradation. RNA isolations were performed on the frozen samples. RNA quality 
was tested via nanodrop spectrophotometry. If the sample contained quality RNA, it was 
reverse transcribed to make cDNA. Finally, cDNA was used as the starting material for 
PCR and selected primers were added. The PCR products were visualized on an 
electrophoresis tray under UV light. 
Methods  
The tibia sample was taken from a mouse specimen during surgery. IACUC 
guidelines were strictly observed and the animal remained anesthetized. After exposing 
the tibia, bone scissors were used to extract the tibia sample. The dissected sample was 
frozen to inactivate RNases and preserve the tissue. See Table 2 for an overview of this 
procedure. 
Table 2 - Tibia Extraction Overview 
Starting Material: Mouse specimen 
Ending Product: Frozen 50 mg mouse tibia sample 
Reagents: - 
Equipment: Bone scissors, test tube 
 
 
For the RNA isolation, first all benchtops were wiped down with RNase Zap wipes 
to eliminate RNases. Liquid nitrogen was used to flash freeze the sample and cool the 
Biopulverizer. Tibia samples were pulverized in the Biopulverizer and placed in a 
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centrifuge tube containing Qiazol solution. The sample was disrupted and homogenized 
under the fume hood using the Tissue Tearor. In the fume hood, chloroform was added to 
the lysate, the tube was vortexed thoroughly, and the solution was incubated, centrifuged, 
and separated. A series of washes and centrifugations purified the RNA in a Qiagen spin 
column. The RNA was eluted with the addition of RNase-free water and an absorbance 
reading was taken using the nanodrop spectrophotometer to assay RNA concentration. 
See Table 3 for an overview of this procedure. 
Table 3 - RNA Isolation Overview 
Starting Material: Frozen 50 mg mouse tibia sample 
Ending Product: Purified RNA 
Reagents: RNeasy Mini Tissue Kit (Qiagen #74104), QIAzol (Qiagen #79306), liquid nitrogen, β-mercaptoethanol 
Equipment: 
BioSpec Biopulverizer, BioSpec Tissue Tearor, forceps, heating 
block, centrifuge, liquid nitrogen container, ice bucket, RNase Zap 
wipes, micropipettes, Nanodrop spectrophotometer 
 
 
To begin the process of reverse transcription, all solutions were thawed, vortexed, 
and centrifuged. RNA samples and oligo(dT) primers were added and the reaction was 
incubated in the thermocycler. The remaining reagents were added. The reaction was 
completed in the thermocycler and the product cDNA was stored at -20°C for future 
PCR. See Table 4 for an overview of this procedure. 
Table 4 - Reverse Transcription Overview 
Starting Material: Purified Quality RNA  
Ending Product: cDNA 
Reagents: AffinityScript Multiple Temperature cDNA Synthesis RT Kit (Agilent #200436) 
Equipment: Ice bucket, RNase Zap wipes, micropipettes 
 
       14 
Following cDNA synthesis, PCR was performed using primers designed for genes 
of interest. A master mix was prepared containing all the components necessary for PCR 
except template cDNA and primers: 10x PCR Buffer, dNTP mix, HotStarTaq DNA 
Polymerase, and RNase-free water. Template cDNA was added to the mix, which was 
then divided among PCR tubes; the primers were added in forward and reverse pairs. 
PCR was performed in the thermocycler, following a cycling protocol similar to the one 
in Table 5, but adjusted to be primer specific. After the PCR reaction completed, the 
products were analyzed by electrophoresis. See Table 6 for an overview of the entire 
PCR procedure. 
Table 5 - Thermocycler Protocol Design 
Initial Activation Step: 15 min 95°C HotStarTaq DNA Polymerase 
requires this heating to activate. 
3-
st
ep
 
cy
cl
e Denaturation: 0.5-1 min 94°C  
Annealing: 0.5-1 min 50-68°C Aim 5°C below Tm of primers. 
Extension: 1 min 72°C  
# of Cycles: 35   
Final Extension: 10 min 72°C  
 
 
 
Table 6 - PCR Overview 
Starting Material: cDNA 
Ending Product: Primer-selected amplified cDNA 
Reagents: HotStarTaq DNA Polymerase Kit (Qiagen #203203), dNTPs, forward and reverse PCR primers (IDT) 
Equipment: BioRad Gradient Thermocycler C1000, PCR tubes, ice bucket, 
micropipettes 
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The gel electrophoresis visualized the amplified cDNA products of PCR. An 
agarose gel was prepared with ethidium bromide. Loading dye was mixed with each PCR 
product and with the standard ladder. The samples were loaded into the gel matrix. After 
electrophoresis, the finished gel matrix was imaged under UV light. By comparing the 
fluorescent bands present in the PCR product lanes to the standard ladder markings, the 
primer-selected genes (if they were present) were identified. See Table 7 for an overview 
of this procedure. 
Table 7 - Gel Electrophoresis Overview 
Starting Material: Primer-selected amplified cDNA 
Ending Product: Visualized and identified cDNA: gene expression data 
Reagents: Loading dye, standard ladder, agarose, ethidium bromide, TAE buffer 
Equipment: 
Electrophoresis: Electrophoresis tray and accessories, electrophoresis 
power supply, microwave, digital balance, spatula, Erlenmeyer flask 
Imaging: UV imager, Canon G10 camera, laptop with camera 
software 
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III Results 
 
Figure 7 - (a) Quality RNA imaged via gel electrophoresis. Left: standard ladder. Middle: sample 1A. 
Right: sample 1B. (b) Column graph of RNA concentration (ng/µL) and RNA purity (A260/280). 
 
Figure 7a is an image of two quality RNA samples obtained using the tibia 
isolation protocol. Both samples displayed the crisp 18S and 28S bands indicative of a 
quality RNA isolate. In theory, the 28S band should be approximately twice as bright as 
the 18S band. For both samples, the 28S band is brighter than the 18S band as expected, 
but without using an alternate technique, the brightness could not be measured 
quantitatively. Figure 7b is a graph of each samples’ nucleic acid concentration and 
260/280 ratio as measured with the nanodrop spectrophotometer. The concentration was 
high enough to use the RNA in a reverse transcription reaction. In quality RNA, the 
260/280 ratio should be approximately 2.0; the sample ratios presented here are excellent.
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Figure 8 - PCR amplicons using cDNA reverse transcribed from RNA isolate 1B. 
 
 
Table 8 - Primers  
 
Gene 5’                      F Primer                      3’ 5’                      R Primer                      3’ Tm 
Ang-1 CCAGAGAATGCCACTCACAATC CAACCACCACAATCACCAGAAT 62.0°C 
Ang-2 CGGAAACTGACTGATGTGGAAG ATTCCAGAGATGTGGGCATTTT 61.9°C 
VEGFa AAGCCTGACATGAAGGAAGAGG CACCGATCTGGGAGAGAGAGAT 62.0°C 
TNF-α ACATTGACAGGTCCAGCAAGAA AAGCACACAGAAAAGCTGCAAG 62.0°C 
TGFβ-1 AAGTCAGAGACGTGGGGACTTC CTTCTCTGTGGAGCTGAAGCAA 62.0°C 
BMP2 TGCCCCCTAGTGCTTCTTAGAC CTTCATGTGCTGGAGTTGAACC 62.0°C 
GAPDH TATGTCGTGGAGTCTACTGGTGTC AGTTGTCATATTTCTCGTGGTTCAC 56.0°C 
β-Actin CTGACAGACTACCTCATGAAGATCC GTCTAGAGCAACATAGCACAGCTTC 58.0°C 
 
 Ladder    Ang-1    Ang-2   VEGFa  TNF-α   TGFβ-1  BMP2  GAPDH  β-Actin 
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Figure 8 above displays the successful results of a PCR performed on a sample of 
cDNA. The cDNA sample was prepared from “DH Tibia RNA 1B” shown in figure 7.  
The PCR was run using a temperature gradient 56-58°C. TGFβ-1 primers created a 
strong amplicon in lane 6 around 1400 base pairs, matching the expected product length 
of 1437 base pairs. GAPDH primers created a very strong amplicon in lane 8 
corresponding to their expected product length. β-Actin primers created a very strong 
amplicon in lane 9 corresponding to their expected product length.  Primer details are 
specified in table 10. 
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IV Discussion 
Success of Methodology 
The three stages of RNA isolation, reverse transcription, and PCR were completed 
successfully. For the RNA isolation, homogenizing the tissue and extracting RNA was 
the most difficult step. The Qiagen RNeasy mini kit protocol was not adapted for bone 
tissue and produced a low yield of RNA, but homogenizing the tibia in Qiazol reagent 
and separating with chloroform solved this problem. This approach yielded a high 
concentration of RNA and avoided degradation. Reverse transcription followed easily. 
PCR proved difficult at first, but optimizing annealing temperature and using previously 
validated primers eventually resulted in success. Future experiments now have a robust 
protocol for investigating gene expression in bone tissue. 
Potential Improvements 
The protocol has room for improvement, however. First, the PCR method 
employed only yields qualitative gene expression data. In order to assay the extent of 
mRNA transcription, quantitative real time PCR must be performed. Transitioning the 
existing protocol to real time PCR will not be difficult; the microcirculation lab already 
uses real time PCR for other molecular biology applications. A second need for 
improvement is to handpick osteocyte gene targets of interest and optimize these primers. 
The primers used in this proof-of-concept study were chosen broadly to look for 
amplification of any kind. Future work will require primers specific to certain osteocyte 
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gene targets of interest. The proper annealing temperatures for these primers will need to 
be established through primer optimization. 
Future Research 
Future research will focus on the connections between osteocyte gene expression, 
angiogenesis, bone remodeling, and osteoporosis. Osteocyte apoptosis is known to 
stimulate angiogenesis, presumably by releasing molecular signaling factors. The 
microcirculation lab plans to examine the angiogenic factors produced by osteocyte 
apoptosis in bone stimulated by axial loading. This is an appropriate follow on to current 
work studying the effects of mechanical stimulus induced osteocyte apoptosis on vascular 
and mechanical properties of bone tissue. A second potential application for the 
microcirculation lab is studying osteocyte gene expression in a mouse model that 
simulates osteoporosis, for instance an aged mouse with impaired remodeling. This will 
yield more information regarding the progression of osteoporosis and the molecular 
reasons for the impaired remodeling observed in cortical and trabecular bone. 
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VI Appendix A: Protocols 
Bone RNA Isolation Qiagen Mini Lipid Tissue Kit 
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Reverse Transcription Agilent AffinityScript Kit 
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Gel Electrophoresis and Spectrophotometry 
 
       27 
Design and Order Primers 
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VII  Appendix B: Experimental Setup 
RNA Isolation Equipment 
 
 
Figure 9 - BioSpec Pulverizer (left) and Tissue Tearor (right). 
 
 
Figure 10 - Nanodrop spectrophotometer for assaying RNA concentration and purity. 
 
 
Figure 11 - Gel electrophoresis apparatus. 
RT and PCR Equipment 
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Figure 12 - BioRad Gradient Thermocycler C1000 (left) and display (right). 
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Comprehensive Reagents/Equipment List 
 
Table 9 - Reagents/Equipment List 
Reagents Category Source Cost 
Agarose Gel Fisher - 
dNTPs PCR Qiagen - 
ethidium bromide Gel Fisher - 
forward and reverse PCR primers PCR IDT $138.40 
liquid nitrogen Isolation Cal Poly - 
Loading dye Gel Fisher - 
Oligo-dT Primers RT Qiagen - 
HotStarTaq DNA Polymerase Kit #203203 PCR Qiagen - 
AffinityScript Multiple Temperature cDNA 
Synthesis Kit, (50) #200436 RT Agilent 
$259.00 
RNeasy Mini Tissue Kit (10) #74104 Isolation Qiagen - 
QIAzol 79306 Isolation Qiagen - 
RNase free water All Fisher - 
RNase inhibitor RT Qiagen - 
standard ladder Gel Fisher - 
TAE buffer Gel Fisher - 
Equipment    
BioRad Gradient Thermocycler C1000 PCR  - 
BioSpec Biopulverizer Isolation  - 
BioSpec Tissue Tearor Isolation  - 
bone scissors Extraction  - 
Canon G10 camera Gel  - 
centrifuge Several  - 
digital balance Gel  - 
electrophoresis power supply Gel  - 
electrophoresis tray and accessories Gel  - 
Erlenmeyer flask Gel  - 
forceps Isolation  - 
heating block Several  - 
ice bucket All  - 
laptop Spec, Gel  - 
liquid nitrogen container Isolation  - 
micropipettes All  - 
microwave Gel  - 
Nanodrop 2000 software Spec  - 
Nanodrop spectrophotometer Spec  - 
PCR tubes PCR  - 
RNase Zap wipes Iso, RT Applied Biosystems - 
spatula Gel  - 
test tubes All  - 
 
